The Opioid Crisis

With nearly 100,000 opioid-related deaths annually in the U.S., the need for effective and long-acting treatments for opioid use disorder (OUD) has never been greater. Traditional options—methadone, buprenorphine, and Vivitrol®—face limitations such as poor adherence, side effects, and high relapse rates.

The APH-1501 Solution

APH-1501 combines low-dose naltrexone (LDN) and cannabidiol (CBD) in a single, intramuscular, extended-release formulation. This non-opioid therapy addresses cravings, anxiety, and relapse using a dual-action mechanism:

– LDN blocks opioid receptors to prevent euphoric effects

– CBD modulates opioid and serotonin (5-HT1A) pathways to ease cravings and stress

Advanced Nanoencapsulation

Using Aphios’ proprietary SuperFluids™ Polymer Nanospheres (SFS-PNS™) platform, APH-1501 ensures:

– Improved CBD bioavailability and stability

– Sustained release for long-term therapeutic action

– Biodegradable, solvent-free delivery system

Market Opportunity

With a projected global OUD treatment market exceeding $16 billion, APH-1501 fills a critical gap for patients and providers seeking safe, effective, and non-opioid-based long-term treatments.

About Aphios Pharma

Aphios Pharma LLC is a biotechnology company focused on developing advanced drug delivery systems and sustainable therapeutics for CNS disorders, cancer, and infectious diseases.

Contact: info@aphios.com | www.aphios.com